A double blinded randomized controlled clinical study to evaluate the efficacy of the Tulasi Ashwagandhadi Herbal Drops on Oxygen Saturation (SPO2) in the management of COVID-19 affected cases.

Charak Hanf Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•Male or female subjects who have been found to be COVID-19 positive
•The Oxygen Concentration level (SpO2) is between 85-95% observable during baseline screening.
•Subjects in the age group 18-65 years (both the ages inclusive).
•Subjects willing to give a written informed consent and agree to come for a regular follow up visit.
•Subjects with mild to moderate level of symptoms pertaining to COVID-19
•Subjects willing to abide by and comply with the study protocol.
•Subjects who have not participated in a similar investigation in the past three months.

•Subjects who have undergone invasive treatments like surgery or other treatment within 3 months before screening into the study.
•Subjects having any active disease which may interfere in the study.
•Any history of underlying uncontrolled medical illness including diabetes mellitus, hypertension, HIV, hepatitis, severe anemia, serious disorder of heart and respiratory apparatus or any other serious medical illness.
•Subjects who have taken chemotherapy for cancer in the 6 months prior to start of the study or have a plan to do treatments during study.
•Subjects (females) who are pregnant or lactating
•A known history or present condition of allergic response/hypersensitivity to any ingredients and pharmaceutical products.
•Chronic illness which may influence the respiratory state.
•Subjects who had been part of any other clinical study within 3 months before screening into the study.

发起方

Charak Hanf Pvt Ltd